These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31709901)

  • 1. Durable response to palbociclib and letrozole in ovarian cancer with
    Frisone D; Charrier M; Clement S; Christinat Y; Thouvenin L; Homicsko K; Michielin O; Bodmer A; Chappuis PO; McKee TA; Tsantoulis P
    Cancer Biol Ther; 2020; 21(3):197-202. PubMed ID: 31709901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
    Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
    Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.
    El Shamieh S; Saleh F; Assaad S; Farhat F
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
    Toulmonde M; Blay JY; Bouche O; Mir O; Penel N; Isambert N; Duffaud F; Bompas E; Esnaud T; Boidot R; Geneste D; Ghiringhelli F; Lucchesi C; Bellera CA; Le Loarer F; Italiano A
    Clin Cancer Res; 2019 Aug; 25(15):4611-4615. PubMed ID: 30979737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    Turner NC; Liu Y; Zhu Z; Loi S; Colleoni M; Loibl S; DeMichele A; Harbeck N; André F; Bayar MA; Michiels S; Zhang Z; Giorgetti C; Arnedos M; Huang Bartlett C; Cristofanilli M
    J Clin Oncol; 2019 May; 37(14):1169-1178. PubMed ID: 30807234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Cottu P; D'Hondt V; Dureau S; Lerebours F; Desmoulins I; Heudel PE; Duhoux FP; Levy C; Mouret-Reynier MA; Dalenc F; Frenel JS; Jouannaud C; Venat-Bouvet L; Nguyen S; Ferrero JM; Canon JL; Grenier J; Callens C; Gentien D; Lemonnier J; Vincent-Salomon A; Delaloge S
    Ann Oncol; 2018 Dec; 29(12):2334-2340. PubMed ID: 30307466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
    Hill SJ; Decker B; Roberts EA; Horowitz NS; Muto MG; Worley MJ; Feltmate CM; Nucci MR; Swisher EM; Nguyen H; Yang C; Morizane R; Kochupurakkal BS; Do KT; Konstantinopoulos PA; Liu JF; Bonventre JV; Matulonis UA; Shapiro GI; Berkowitz RS; Crum CP; D'Andrea AD
    Cancer Discov; 2018 Nov; 8(11):1404-1421. PubMed ID: 30213835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
    Köbel M; Huntsman D; Gilks CB
    Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients.
    Niu Y; Sun W; Chen K; Fu Z; Chen Y; Zhu J; Chen H; Shi Y; Zhang H; Wang L; Shen HM; Xia D; Wu Y
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2106-2114. PubMed ID: 31533939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR
    Brufsky A; Mitra D; Davis KL; Nagar SP; McRoy L; Cotter MJ; Stearns V
    Clin Breast Cancer; 2019 Oct; 19(5):317-325.e4. PubMed ID: 31104984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
    Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
    J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
    Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
    Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
    J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.